# CEFUROXIME AXETIL - cefuroxime axetil tablet

## LUPIN LIMITED

---

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS USP safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS USP.

**CEFUROXIME axetil tablets USP, for oral use**

**Initial U.S. Approval: 1987**

---

### INDICATIONS AND USAGE

- **Pharyngitis/Tonsillitis** (adults and pediatric patients 13 years and older)
- **Acute bacterial maxillary sinusitis** (adults and pediatric patients 13 years and older)
- **Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis** (adults and pediatric patients 13 years and older)
- **Uncomplicated skin and skin-structure infections** (adults and pediatric patients 13 years and older)
- **Uncomplicated urinary tract infections** (adults and pediatric patients 13 years and older)
- **Early Lyme disease** (adults and pediatric patients 13 years and older)

---

### DOSAGE AND ADMINISTRATION

- **Tablets and oral suspension** are not bioequivalent and are therefore not substitutable on a milligram-per-milligram basis. (2.1)
- **Administer tablets** with or without food. (2.2)
- **Administer cefuroxime axetil tablets USP** as described in the dosage guidelines. (2.3)
- **Dosage adjustment** is required for patients with impaired renal function. (2.4)

---

### ADVERSE REACTIONS

- **Clostridium difficile-associated diarrhea (CDAD):** If diarrhea occurs, evaluate patients for CDAD. (5.1)

---

### CONTRAINDICATIONS

- **Known hypersensitivity to cefuroxime axetil tablets or to other β-lactams (e.g., penicillins and cephalosporins).**
- **Known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil tablets or to other β-lactams (e.g., penicillins and cephalosporins).**

---

### DRUG INTERACTIONS

- **Co-administration with probenecid increases systemic exposure to cefuroxime axetil tablets.**
- **Drugs that reduce gastric acidity may lower the bioavailability of cefuroxime axetil tablets.**

---

### CONTRAINDICATIONS

- **Bacterial strains resistant to cefuroxime axetil tablets USP:** Cefuroxime axetil tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

---

### DOSAGE FORMS AND STRENGTHS

<table>
<thead>
<tr>
<th>Infection</th>
<th>Dosage</th>
<th>Duration (Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharyngitis/tonsillitis (adults)</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Acute bacterial maxillary sinusitis (adults)</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Acute bacterial exacerbations of chronic bronchitis (adults)</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Secondary bacterial infections of acute bronchitis (adults)</td>
<td>250 mg every 12 hours</td>
<td>5-10</td>
</tr>
<tr>
<td>Uncomplicated skin and skin-structure infections (adults)</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Uncomplicated urinary tract infections (adults)</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Early Lyme disease (adults)</td>
<td>3,000 mg single dose</td>
<td></td>
</tr>
<tr>
<td>Pediatric Patients younger than 13 years (who can swallow tablets whole)</td>
<td>500 mg every 12 hours</td>
<td>20</td>
</tr>
<tr>
<td>Acute bacterial otitis media (adults)</td>
<td>250 mg every 12 hours</td>
<td></td>
</tr>
<tr>
<td>Acute bacterial maxillary sinusitis (adults)</td>
<td>250 mg every 12 hours</td>
<td></td>
</tr>
</tbody>
</table>

---

### FULL PRESCRIBING INFORMATION: CONTENTS*

1. **INDICATIONS AND USAGE**
   - 1.1 Pharyngitis/Tonsillitis
   - 1.2 Acute Bacterial Otitis Media
   - 1.3 Acute Bacterial Maxillary Sinusitis
   - 1.4 Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis
   - 1.5 Uncomplicated Skin and Skin-structure Infections
   - 1.6 Uncomplicated Urinary Tract Infections
   - 1.7 Uncomplicated Gonorrhea
   - 1.8 Early Lyme Disease (erythema migrans)
   - 1.10 Usage

2. **DOSAGE AND ADMINISTRATION**
   - 2.1 Important Administration Instructions
   - 2.2 Dosage for cefuroxime axetil tablets USP
   - 2.3 Dosage in Patients with Impaired Renal Function

3. **DOSAGE FORMS AND STRENGTHS**

4. **CONTRAINDICATIONS**

5. **WARNINGS AND PRECAUTIONS**

6. **ADVERSE REACTIONS**

7. **DRUG INTERACTIONS**
   - 7.1 Oral Contraceptives
   - 7.2 Drugs that Reduce Gastric Acidity
   - 7.3 Probenecid
   - 7.4 Drug/Laboratory Test Interactions

8. **USE IN SPECIFIC POPULATIONS**
   - 8.1 Pregnancy
   - 8.2 Nursing Mothers

---

*See 17 for PATIENT COUNSELING INFORMATION.*

Revised: 5/2016
1 INDICATIONS AND USAGE

1.1 Pharyngitis/Tonsillitis

Cefuroxime axetil tablets USP are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of Streptococcus pyogenes.

Limitations of Use

- The efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials.
- The efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of Streptococcus pyogenes has not been demonstrated in clinical trials.

1.2 Acute Bacterial Otitis Media

Cefuroxime axetil tablets USP are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase–producing strain), Moraxella catarrhalis (including β-lactamase–producing strain), or Streptococcus pyogenes.

1.3 Acute Bacterial Maxillary Sinusitis

Cefuroxime axetil tablets USP are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae (non-β-lactamase–producing strains only).

Limitations of Use

The effectiveness of cefuroxime axetil for sinus infections caused by β-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis in patients with acute bacterial maxillary sinusitis was not established due to insufficient numbers of these isolates in the clinical trials [see CLINICAL STUDIES (14.1)].

1.4 Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis

Cefuroxime axetil tablets USP are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with mild-to-moderate acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae (β-lactamase–negative strain), or Haemophilus parainfluenzae (β-lactamase–negative strain).

1.5 Uncomplicated Skin and Skin-structure Infections

Cefuroxime axetil tablets USP are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated skin and skin-structure infections caused by susceptible strains of Staphylococcus aureus (including β-lactamase–producing strain) or Streptococcus pyogenes.

1.6 Uncomplicated Urinary Tract Infections

Cefuroxime axetil tablets USP are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated urinary tract infections caused by susceptible strains of Escherichia coli or Klebsiella pneumoniae.

1.7 Uncomplicated Gonorrhea

Cefuroxime axetil tablets USP are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated gonorrhea, urethral and endocervical, caused by penicillinase producing and non-penicillinase–producing susceptible strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing susceptible strains of Neisseria gonorrhoeae.

1.8 Early Lyme Disease (erythema migrans)

Cefuroxime axetil tablets USP are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with early Lyme disease (erythema migrans) caused by susceptible strains of Borrelia burgdorferi.

1.9 Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

- Cefuroxime axetil tablets USP and cefuroxime axetil for oral suspension are not bioequivalent and are therefore not substitutable on a milligram-per-milligram basis [see CLINICAL PHARMACOLOGY (12.3)].
- Administer cefuroxime axetil tablets USP as described in the appropriate dosage guidelines [see DOSAGE AND ADMINISTRATION (2.2)].
- Administer cefuroxime axetil tablets USP with or without food.
- Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets USP...
2.2 Dosage for cefuroxime axetil tablets USP

Administer cefuroxime axetil tablets USP as described in the dosage guidelines table below with or without food.

Table 1. Adult Patients and Pediatric Patients Dosage Guidelines for Cefuroxime Axetil Tablets USP

<table>
<thead>
<tr>
<th>Infection</th>
<th>Dosage</th>
<th>Duration (Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharyngitis/tonsillitis (mild to moderate)</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Acute bacterial maxillary sinusitis (mild to moderate)</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Acute bacterial exacerbation of chronic bronchitis (mild to moderate)</td>
<td>250 or 500 mg every 12 hours²</td>
<td>10</td>
</tr>
<tr>
<td>Secondary bacterial infections of acute bronchitis</td>
<td>250 or 500 mg every 12 hours²</td>
<td>5 to 10</td>
</tr>
<tr>
<td>Uncomplicated skin and skin-structure infections</td>
<td>250 or 500 mg every 12 hours²</td>
<td>10</td>
</tr>
<tr>
<td>Uncomplicated urinary tract infections</td>
<td>250 mg every 12 hours</td>
<td>7 to 10</td>
</tr>
<tr>
<td>Uncomplicated gonorrhea</td>
<td>1,000 mg</td>
<td>single dose</td>
</tr>
<tr>
<td>Early Lyme disease</td>
<td>500 mg every 12 hours</td>
<td>20</td>
</tr>
<tr>
<td>Pediatric Patients younger than 13 years (who can swallow tablets whole)³</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Acute bacterial otitis media</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
<tr>
<td>Acute bacterial maxillary sinusitis</td>
<td>250 mg every 12 hours</td>
<td>10</td>
</tr>
</tbody>
</table>

2.5 Dosage in Patients with Impaired Renal Function

A dosage interval adjustment is required for patients whose creatinine clearance is <30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney (see CLINICAL PHARMACOLOGY (12.3)).

Table 4. Dosing in Adults with Renal Impairment

<table>
<thead>
<tr>
<th>Creatinine Clearance (mL/min)</th>
<th>Recommended Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤30</td>
<td>No dosage adjustment</td>
</tr>
<tr>
<td>30 to 130</td>
<td>Standard individual dose given every 24 hours</td>
</tr>
<tr>
<td>&gt;130 (without hemodialysis)</td>
<td>Standard individual dose given every 48 hours</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>A single additional standard dose should be given at the end of each dialysis</td>
</tr>
</tbody>
</table>

3 DOSE FORMS AND STRENGTHS

Cefuroxime axetil tablets are off-white, capsule-shaped, film-coated tablets available in the following strengths:

- 250 mg of cefuroxime (as cefuroxime axetil) are white to off-white capsule-shaped, film-coated tablets with “LUPIN” debossed on one side and “302” on the other side.
- 500 mg of cefuroxime (as cefuroxime axetil) are white to off-white capsule-shaped, film-coated tablets with “LUPIN” debossed on one side and “303” on the other side.

4 CONTRAINDICATIONS

Cefuroxime axetil is contraindicated in patients with a known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins).

5 WARNINGS AND PRECAUTIONS

5.1 Anaphylactic Reactions

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on β-lactam antibacterials. These reactions are more likely to occur in individuals with a history of β-lactam hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Cefuroxime axetil is contraindicated in patients with a known hypersensitivity to cefuroxime axetil or other β-lactam antibacterial drugs (see CONTRAINDICATIONS (4)). Before initiating therapy with cefuroxime axetil, inquire about previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, discontinue cefuroxime axetil and institute appropriate therapy.

5.2 Clostridium difficile-associated Diarrhea

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefuroxime axetil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.3 Potential for Microbial Overgrowth

The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy.

5.4 Development of Drug-resistant Bacteria

Prescribing cefuroxime axetil either in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

5.5 Interference with Glucose Tests

A false-positive result for glucose in the urine may occur with copper reduction tests, and a false-negative result for blood/plasma glucose may occur with ferricyanide tests in subjects receiving cefuroxime axetil (see DRUG INTERACTIONS (7.4)).

6 ADVERSE REACTIONS

The following serious and otherwise important adverse reactions is described in greater detail in the Warnings and Precautions section of the label:

Anaphylactic Reactions (see WARNINGS AND PRECAUTIONS (5.1))

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another
Increased prothrombin time.

Investigations

Immune System Disorders

Hepatic impairment including hepatitis and cholestasis, jaundice.

Hepatobiliary Disorders

Pseudomembranous colitis

Gastrointestinal Disorders

Hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia.

Blood and Lymphatic System Disorders

possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions have been identified during post-approval use of cefuroxime axetil.

6.2 Postmarketing Experience

Reproductive System and Breast Disorders:

Renal and Urinary Disorders:

Skin and Subcutaneous Tissue Disorders:

Gastrointestinal Disorders:

Cardiac Disorders:

Nervous System Disorders:

Metabolism and Nutrition Disorders:

Immune System Disorders:

Kidney pain. It is noted that 125 mg twice daily is not an approved dosage. Twenty (2.2%) subjects discontinued medication due to adverse reactions. Seventeen (85%) of the 20 subjects who discontinued therapy did so because of gastrointestinal disturbances, including diarrhea, nausea, vomiting, and abdominal pain. The percentage of subjects with gastrointestinal adverse reactions increased with the higher recommended doses. The incidence of gastrointestinal adverse reactions increased with the higher recommended doses.

The adverse reactions in Table 5 for subjects (n = 912) treated with cefuroxime axetil in multiple-dose clinical trials.

Table 5. Adverse Reactions (≥1%) after Multiple-dose Regimens with Cefuroxime Axetil Tablets

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Cefuroxime Axetil Tablets (n = 912)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
</tr>
<tr>
<td>Eosinophilia</td>
<td>3%</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4%</td>
</tr>
<tr>
<td>Nausea/Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
</tr>
<tr>
<td>Transient elevation in AST</td>
<td>2%</td>
</tr>
<tr>
<td>Transient elevation in ALT</td>
<td>2%</td>
</tr>
<tr>
<td>Transient elevation in LDH</td>
<td>3%</td>
</tr>
</tbody>
</table>

The following adverse reactions occurred in less than 1% but greater than 0.1% of subjects (n = 912) treated with cefuroxime axetil in multiple-dose clinical trials.

Metabolism and Nutrition Disorders: Anorexia.

Nervous System Disorders: Headache.

Cardiac Disorders: Chest pain.

Respiratory Disorders: Shortness of breath.

Gastrointestinal Disorders: Abdominal pain, abdominal cramps, flatulence, indigestion, mouth ulcers.

Skin and Subcutaneous Tissue Disorders: Rash, itch.

Renal and Urinary Disorders: Dysuria.

Reproductive System and Breast Disorders: Vaginitis, vulvar itch.

General Disorders and Administration Site Conditions: Chills, sleepiness, thirst.

Investigations: Positive Coombs’ test.

5-Day Regimen: In clinical trials using cefuroxime axetil tablets 250 mg twice daily in the treatment of secondary bacterial infections of acute bronchitis, 389 subjects were treated for 5 days and 402 subjects were treated for 10 days. No difference in the occurrence of adverse reactions was found between the 2 regimens.

Early Lyme Disease with 20-Day Regimen: Two multicenter trials assessed cefuroxime axetil tablets 500 mg twice daily for 20 days. The most common drug-related adverse experiences were diarrhea (10.6%), Jarisch-Herxheimer reaction (5.6%), and vaginitis (5.4%). Other adverse experiences occurred with frequencies comparable to those reported with 7 to 10 days' dosing.

Single-dose Regimen for Uncomplicated Gonorrhea: In clinical trials using a single 1,000 mg dose of cefuroxime axetil tablets, 1,061 subjects were treated for uncomplicated gonorrhea.

The adverse reactions in Table 6 were for subjects treated with a single dose of 1,000 mg cefuroxime axetil tablets in US clinical trials.

Table 6. Adverse Reactions (≥1%) after Single-dose Regimen with 1,000-mg Cefuroxime Axetil Tablets for Uncomplicated Gonorrhea

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Cefuroxime Axetil Tablets (n = 1,061)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
</tr>
<tr>
<td>Nausea/Vomiting</td>
<td>7%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4%</td>
</tr>
</tbody>
</table>

The following adverse reactions occurred in less than 1% but greater than 0.1% of subjects (n = 1,061) treated with cefuroxime axetil in single-dose clinical trials.

Infections and Infestations: Vaginal candidiasis.

Nervous System Disorders: Headache, dizziness, somnolence.

Cardiac Disorders: Tightness/pain in chest, tachycardia.

Gastrointestinal Disorders: Abdominal pain, dyspepsia.

Skin and Subcutaneous Tissue Disorders: Erythema, rash, pruritus.

Musculoskeletal and Connective Tissue Disorders: Muscle cramps, muscle stiffness, muscle spasm of neck, lockjaw-type reaction.

Renal and Urinary Disorders: Bleeding/pain in urethra, kidney pain.

Reproductive System and Breast Disorders: Vaginal itch, vaginal discharge.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of cefuroxime axetil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic System Disorders:

Hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia.

Gastrointestinal Disorders

Pseudomembranous colitis [see WARNINGS AND PRECAUTIONS (5.2)].

Hepatobiliary Disorders

Hepatic impairment including hepatitis and cholestasis, jaundice.

Immune System Disorders

Anaphylaxis, serum sickness-like reaction.

Investigations

Increased prothrombin time.
Cefuroxime axetil is in the amorphous form and has the following structural formula:

\[ \text{molecular formula is } C_{12}H_{22}N_{7}O_{10}S_{3} \]

The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is a semisynthetic, cephalosporin antibacterial drug for oral administration.

Cefuroxime axetil tablets USP contain cefuroxime as cefuroxime axetil. Cefuroxime axetil is a 11 DESCRIPTION

Cefuroxime axetil tablets USP contain cefuroxime as cefuroxime axetil. Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration.

The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is (RS)-1-hydroxyethyl (6R,7R)-7-[(2-furyl)glyoxylamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]-oct-2-yl-2-carboxylate, 7-(Z)-(O-methyl oxime), 1-acetate 3-carbamate. Its molecular formula is C_{20}H_{28}N_{7}O_{10}S_{3} and it has a molecular weight of 510.48.

Cefuroxime axetil is in the amorphous form and has the following structural formula:
Cefuroxime axetil tablets USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil. Cefuroxime axetil tablets USP contain the inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hydrogenated vegetable oil, hypromellose, microcrystalline cellulose, propylene glycol, polyethylene glycol, sodium lauryl sulfate, talc and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
Cefuroxime axetil is an antibacterial drug [see CLINICAL PHARMACOLOGY (12.4)].

12.3 Pharmacokinetics

Absorption
After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime. Serum pharmacokinetic parameters for cefuroxime following administration of cefuroxime axetil tablets to adults are shown in Table 8.

Table 8. Pharmacokinetics of Cefuroxime Administered in the Postprandial State as Cefuroxime Axetil Tablets to Adults

<table>
<thead>
<tr>
<th>Dose (mg)</th>
<th>Peak Plasma Concentration (mcg/mL)</th>
<th>Time of Peak Plasma Concentration (h)</th>
<th>Mean Elimination Half-life (h)</th>
<th>AUC (mcg*h/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>125</td>
<td>2.1</td>
<td>2.2</td>
<td>1.2</td>
<td>6.7</td>
</tr>
<tr>
<td>250</td>
<td>4.1</td>
<td>2.5</td>
<td>1.2</td>
<td>12.9</td>
</tr>
<tr>
<td>500</td>
<td>7.0</td>
<td>3.0</td>
<td>1.2</td>
<td>27.4</td>
</tr>
<tr>
<td>1,000</td>
<td>13.6</td>
<td>2.5</td>
<td>1.3</td>
<td>50.0</td>
</tr>
</tbody>
</table>

* Mean values of 12 healthy adult volunteers.
† Drug administered immediately after a meal.

Food Effect: Absorption of the tablet is greater when taken after food (absolute bioavailability increases from 37% to 52%). Despite this difference in absorption, the clinical and bacteriologic responses of subjects were independent of food intake at the time of tablet administration in 2 trials where this was assessed.

All pharmacokinetic and clinical effectiveness and safety trials in pediatric subjects using the suspension formulation were conducted in the fed state. No data are available on the absorption kinetics of the suspension formulation when administered to fasted pediatric subjects.

Lock of Bioequivalence: Oral suspension was not bioequivalent to tablets when tested in healthy adults. The tablet and oral suspension formulations are NOT substitutable on a milligram-per-milligram basis. The area under the curve for the suspension averaged 91% of that for the tablet, and the peak plasma concentration for the suspension averaged 71% of the peak plasma concentration of the tablets. Therefore, the safety and effectiveness of both the tablet and oral suspension formulations were established in separate clinical trials.

Distribution
Cefuroxime is distributed throughout the extracellular fluids. Approximately 50% of serum cefuroxime is bound to protein.

Metabolism
The axetil moiety is metabolized to acetaldehyde and acetic acid.

Excretion
Cefuroxime is excreted unchanged in the urine; in adults, approximately 50% of the administered dose is recovered in the urine within 12 hours. The pharmacokinetics of cefuroxime in pediatric subjects have not been studied. Until further data are available, the renal elimination of cefuroxime axetil established in adults should not be extrapolated to pediatric subjects.

Specific Populations

Geriatric Patients: In a trial of 20 elderly subjects (mean age = 83.9 years) having a mean creatinine clearance of 34.9 mL/min, the mean serum elimination half-life was prolonged to 3.5 hours; however, despite the lower elimination of cefuroxime in geriatric patients, dosage adjustment based on age is not necessary [see USE IN SPECIFIC POPULATIONS (8.5)].

Drug Interactions
Concomitant administration of probenecid with cefuroxime axetil tablets increases the cefuroxime area under the serum concentration versus time curve and maximum serum concentration by 50% and 21%, respectively.

12.4 Microbiology

Mechanism of Action
Cefuroxime axetil is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime axetil has activity in the presence of some β-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria.

Mechanism of Resistance
Resistance to cefuroxime axetil is primarily through hydrolysis by β-lactamase, alteration of penicillin-binding protein (PBPs), decreased permeability, and the presence of bacterial efflux pumps. Susceptibility to cefuroxime axetil will vary with geography and time; local susceptibility data should be consulted, if available. Beta-lactamase-negative, ampicillin-resistant (BLNAR) isolates of H. influenzae should be considered resistant to cefuroxime axetil.
Cefuroxime axetil has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections: [see INDICATIONS AND USAGE (1)]:

- **Gram-positive bacteria**
  - Staphylococcus aureus (methicillin-susceptible isolates only)
  - Streptococcus pneumoniae
  - Streptococcus pyogenes
- **Gram-negative bacteria**
  - Escherichia coli
  - Klebsiella pneumoniae
  - Haemophilus influenzae
  - Haemophilus parainfluenzae
  - Moraxella catarrhalis

Neisseria gonorrhoeae

- Most extended spectrum β-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefuroxime axetil.
- Spirochetes
  - *Borrelia burgdorferi*

The following in vitro data are available, but their clinical significance is unknown. At least 98 percent of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefuroxime axetil of 1 mcg/mL.

However, the efficacy of cefuroxime axetil in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.

- **Gram-positive bacteria**
  - Staphylococcus epidermidis (methicillin-susceptible isolates only)
  - Staphylococcus saprophyticus (methicillin-susceptible isolates only)
  - Streptococcus agalactiae
  - Staphylococcus epidermidis
  - Staphylococcus epidermidis
  - Peptococcus niger

**Susceptibility Test Methods**

When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility tests for antimicrobial drug products used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.

**Dilution Techniques**: Quantitative methods are used to determine antimicrobial MICs. These MICs provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth or agar). The MIC values should be interpreted according to criteria provided in Table 10.3

**Diffusion Techniques**: Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. This category provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method. This procedure uses paper disks impregnated with 30 mcg cefuroxime axetil to test the susceptibility of microorganisms to cefuroxime axetil. The disk diffusion interpretive criteria are provided in Table 10.3

**Table 10. Susceptibility Test Interpretive Criteria for Cefuroxime Axetil**

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>(S)</th>
<th>Inhibitory</th>
<th>Intermediate</th>
<th>Resistant</th>
<th>(S)</th>
<th>Inhibitory</th>
<th>Intermediate</th>
<th>Resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enterobacteriaceae*</td>
<td>≤4</td>
<td>8 to 16</td>
<td>≥32</td>
<td>≥23</td>
<td>15</td>
<td>22</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Haemophilus spp.†</td>
<td>≤4</td>
<td>8</td>
<td>≥16</td>
<td>≥20</td>
<td>17</td>
<td>19</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Moraxella catarrhalis*</td>
<td>≤4</td>
<td>8</td>
<td>≥16</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Streptococcus pneumonia†</td>
<td>≤1</td>
<td>2</td>
<td>≥4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* For Enterobacteriaceae, Haemophilus spp., and Moraxella catarrhalis, susceptibility interpretive criteria are based on a dose of 500 mcg every 12 hours in patients with normal renal function.

† Haemophilus spp. includes only isolates of *H. influenzae* and *H. parainfluenzae*.

A report of "Susceptible" indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of "Intermediate" indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection; other therapy should be selected.

**Quality Control**: Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test. The QC ranges for MIC and disk diffusion testing using the 30-mcg disk are provided in Table 11.3

**Table 11. Acceptable Quality Control (QC) Ranges for Cefuroxime Axetil**

<table>
<thead>
<tr>
<th>QC Strain</th>
<th>Minimum Inhibitory Concentrations (mcg/mL)</th>
<th>Disk Diffusion Zone Diameters (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Escherichia coli ATCC 25922</td>
<td>2 to 8</td>
<td>20 to 26</td>
</tr>
<tr>
<td>Staphylococcus aureus ATCC 25923</td>
<td>-</td>
<td>27 to 35</td>
</tr>
<tr>
<td>Staphylococcus aureus ATCC 29213</td>
<td>0.5 to 2</td>
<td>-</td>
</tr>
<tr>
<td>Streptococcus pneumonia ATCC 49619</td>
<td>0.25 to 1</td>
<td>-</td>
</tr>
<tr>
<td>Haemophilus influenza ATCC 49766</td>
<td>0.25 to 1</td>
<td>28 to 36</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae ATCC 49326</td>
<td>0.25 to 1</td>
<td>33 to 41</td>
</tr>
</tbody>
</table>

ATCC = American Type Culture Collection.
13 NONCLINICAL TOXICOLOGY

13.3 Carcinogenesis, Mutagenesis, Impairment of Fertility

Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime axetil in a battery of bacterial mutagenicity tests. Positive results were obtained in an in vitro chromosome aberration assay; however, negative results were found in in vivo micronucleus test at doses up to 1.5 g/kg. Reproduction studies in rats at doses up to 1,000 mg/kg/day (9 times the recommended maximum human dose based on body surface area) have revealed no impairment of fertility.

14 CLINICAL STUDIES

14.1 Acute Bacterial Maxillary Sinusitis

One adequate and well-controlled trial was performed in subjects with acute bacterial maxillary sinusitis. In this trial, each subject had a maxillary sinus aspirate collected by sinus puncture before treatment was initiated for presumptive acute bacterial sinusitis. All subjects had radiographic and clinical evidence of acute maxillary sinusitis. In the trial, the clinical effectiveness of cefuroxime axetil in treating acute maxillary sinusitis was comparable to an oral antimicrobial agent containing a specific β-lactamase inhibitor. However, microbiology data demonstrated cefuroxime axetil to be effective in treating acute bacterial maxillary sinusitis due only to Streptococcus pneumoniae or non-β-lactamase–producing Haemophilus influenzae. Insufficient numbers of β-lactamase–producing Haemophilus influenzae and Moraxella catarrhalis isolates were obtained in this trial to adequately evaluate the effectiveness of cefuroxime axetil in treating acute bacterial maxillary sinusitis due to these 2 organisms.

This trial randomized 317 adult subjects, 132 subjects in the United States and 185 subjects in South America. Table 12 shows the results of the intent-to-treat analysis.

### Table 12. Clinical Effectiveness of Cefuroxime Axetil Tablets in the Treatment of Acute Bacterial Maxillary Sinusitis

<table>
<thead>
<tr>
<th>US Subjects</th>
<th>South American Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cefuroxime Axetil Tablets 250 mg Twice Daily (n = 43)</td>
</tr>
<tr>
<td></td>
<td>Cefuroxime Axetil Tablets 250 mg Twice Daily (n = 43)</td>
</tr>
<tr>
<td>Clinical success (cure + improvement)</td>
<td>65%</td>
</tr>
<tr>
<td>Clinical cure</td>
<td>53%</td>
</tr>
<tr>
<td>Clinical improvement</td>
<td>12%</td>
</tr>
</tbody>
</table>

* 95% confidence interval around the success difference [-0.08, +0.32].
† 95% confidence interval around the success difference [-1.00, +0.16].

In this trial and in a supporting maxillary puncture trial, 15 evaluable subjects had non-β-lactamase–producing Haemophilus influenzae as the identified pathogen. Of these, 6/15 (40%) had this pathogen eradicated. Eighteen (18) evaluable subjects had Streptococcus pneumoniae as the identified pathogen. Of these, 13/18 (72%) had this pathogen eradicated.

14.2 Lyme Disease

Two adequate and well-controlled trials were performed in subjects with early Lyme disease. All subjects presented with physician-documented erythema migrans, with or without systemic manifestations of infection. Subjects were assessed at 1 month of posttreatment for success in treating early Lyme disease (Part I) and at 1 year posttreatment for success in preventing the progression to the sequelae of late Lyme disease (Part II). A total of 385 adult subjects (181 treated with cefuroxime axetil and 174 treated with doxycycline) were randomized in the 2 trials, with diagnosis of early Lyme disease confirmed in 79% (281/355). The clinical diagnosis of early Lyme disease in these subjects was validated by 1) blinded expert reading of photographs, when available, of the pretreatment erythema migrans skin lesion, and 2) serologic confirmation (using enzyme-linked immunosorbent assay [ELISA] and immunoblot assay [Western blot]) of the presence of antibodies specific to Borrelia burgdorferi, the etiologic agent of Lyme disease. The efficacy data in Table 14 are specific to the “validated” patient subset, while the safety data below reflect the entire patient population for the 2 trials. Clinical data for evaluable subjects in the “validated” patient subset are shown in Table 13.

### Table 13. Clinical Effectiveness of Cefuroxime Axetil Tablets Compared with Doxycycline in the Treatment of Early Lyme Disease

<table>
<thead>
<tr>
<th>Part I (1 Month after 20 Days of Treatment)*</th>
<th>Part II (1 Year after 20 Days of Treatment)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefuroxime Axetil Tablets 500 mg Twice Daily</td>
<td>Cefuroxime Axetil Tablets 500 mg Twice Daily</td>
</tr>
<tr>
<td>(n = 125)</td>
<td>(n = 43)</td>
</tr>
<tr>
<td>Dicycline 100 mg 3 Times Daily (n = 125)</td>
<td>Dicycline 100 mg 3 Times Daily (n = 43)</td>
</tr>
<tr>
<td>Satisfactory clinical outcome§</td>
<td>91%</td>
</tr>
<tr>
<td>Clinical cure/success</td>
<td>72%</td>
</tr>
<tr>
<td>Clinical improvement</td>
<td>19%</td>
</tr>
</tbody>
</table>

* 95% confidence interval around the satisfactory difference for Part I [-0.08, +0.05].
† 95% confidence interval around the satisfactory difference for Part II [-0.13, +0.07].
‡ n’s include subjects assessed as unsatisfactory clinical outcomes (failure + recurrence) in Part I (Cefuroxime Axetil Tablets - 11 [5 failure, 6 recurrence]; doxycycline - 8 [6 failure, 2 recurrence]).
§ Satisfactory clinical outcome includes cure + improvement (Part I) and success + improvement (Part II).

Cefuroxime axetil and doxycycline were effective in prevention of the development of sequelae of late Lyme disease. While the incidence of drug-related gastrointestinal adverse reactions was similar in the 2 treatment groups (cefuroxime axetil - 13%; doxycycline - 11%), the incidence of drug-related diarrhea was higher in the cefuroxime axetil arm versus the doxycycline arm (11% versus 8%, respectively).

14.3 Secondary Bacterial Infections of Acute Bronchitis

Four randomized, controlled clinical trials were performed comparing 5 days versus 10 days of cefuroxime axetil for the treatment of subjects with secondary bacterial infections of acute bronchitis. These trials enrolled a total of 1,253 subjects (Study 1 n = 360; Study 2 n = 177; Study 3 n = 362; Study 4 n = 354). The protocols for Study 1 and Study 2 were identical and compared cefuroxime axetil 250 mg twice daily for 5 days, cefuroxime axetil 250 mg twice daily for 10 days, and AUGMENTIN® (amoxicillin/clavulinate potassium) 500 mg 3 times daily for 10 days. These 2 trials were conducted simultaneously. Study 3 and Study 4 compared cefuroxime axetil 250 mg twice daily for 5 days, cefuroxime axetil 250 mg twice daily for 10 days, and CECLOR^® (cefaclor) 250 mg 3 times daily for 10 days. They were otherwise identical to Study 1 and Study 2 and were conducted over the following 2 years. Subjects were required to have polymorphonuclear cells present on the Gram stain of their screening sputum specimen, but isolation of a bacterial pathogen from the sputum culture was not required for inclusion.

Table 14 demonstrates the results of the clinical outcome analysis of the pooled trials Study 1/Study 2 and Study 3/Study 4, respectively.

### Table 14. Clinical Effectiveness of Cefuroxime Axetil Tablets 250 mg Twice Daily in Secondary Bacterial Infections of Acute Bronchitis: Comparison of 5 versus 10 Days’ Treatment Duration

<table>
<thead>
<tr>
<th>Study 1 and Study 2*</th>
<th>Study 3 and Study 4**</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 Day</td>
<td>5 Day</td>
</tr>
<tr>
<td>10 Day</td>
<td>10 Day</td>
</tr>
</tbody>
</table>

* n’s include subjects assessed as unsatisfactory clinical outcomes (failure + recurrence) in Part I (Cefuroxime Axetil Tablets - 11 [5 failure, 6 recurrence]; doxycycline - 8 [6 failure, 2 recurrence]).
Clinical success (cure + improvement) 80% 87% 84% 82%
Clinical cure 61% 70% 73% 72%
Clinical improvement 19% 17% 11% 10%
* 95% confidence interval around the success difference [-0.164, +0.029].
† 95% confidence interval around the success difference [-0.061, +0.103].
The response rates for subjects who were both clinically and bacteriologically evaluable were consistent with those reported for the clinically evaluable subjects.

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING
Cefuroxime axetil tablets USP, 250 mg of cefuroxime (as cefuroxime axetil), are white to off-white capsule-shaped, film-coated tablets with “LUPIN” debossed on one side and “302” on the other side, supplied in bottles of 20 and 60.
20s Bottle NDC 68180-302-20
60s Bottle NDC 68180-302-60
Cefuroxime axetil tablets USP, 500 mg of cefuroxime (as cefuroxime axetil), are white to off-white capsule-shaped, film-coated tablets with “LUPIN” debossed on one side and “303” on the other side, supplied in bottles of 20 and 60.
20s Bottle NDC 68180-303-20
60s Bottle NDC 68180-303-60
Store the tablets at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION
Allergic Reactions
Inform patients that cefuroxime axetil is a cephalosporin that can cause allergic reactions in some individuals [see WARNINGS AND PRECAUTIONS (5.1)].

Clostridium difficile-associated Diarrhea
Inform patients that diarrhea is a common problem caused by antibiotics, and it usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, advise patients to contact their physician as soon as possible.

Crushing Tablets
Inform patients to swallow the tablet whole, without crushing the tablet. Patients who cannot swallow the tablet whole should receive the oral suspension.

Drug Resistance
Inform patients that antibiotic drugs, including cefuroxime axetil, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefuroxime axetil is prescribed to treat a bacterial infection, inform patients that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefuroxime axetil or other antibacterial drugs in the future.

AUGMENTIN is registered trademark of the GSK group of companies.
Manufactured for:
Lupin Pharmaceuticals, Inc.
Baltimore, Maryland 21202
United States.
Manufactured by:
Lupin Limited
Mandideep 462 046
INDIA.
Revised: November 2015
ID#: 243305
Cefuroxime Axetil Tablets USP - 250 mg – Bottle of 20s - NDC 68180-302-20
Bottles of 20 -
Cefuroxime Axetil Tablets USP - 500 mg – Bottle of ...
Cefuroxime Axetil Tablets USP
250 mg – Bottle of 20s
NDC 68180-302-20
Cefuroxime Axetil Tablets USP
500 mg – Bottle of 20s
NDC 68180-303-20 Bottles of 20

<table>
<thead>
<tr>
<th>NDC: 57297-302-20</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 mg * Each film-coated tablet contains cefuroxime axetil USP (amorphous) equivalent to 500 mg of cefuroxime. Rx only</td>
</tr>
</tbody>
</table>

**Product Information**

**Product Type**
- HUMAN PRESCRIPTION DRUG

**Route of Administration**
- ORAL

**Active Ingredient/Active Moiety**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEFUROXIME AXETIL (UNII: Z49QDT0J8Z) (CEFUROXIME - UNII:O1R9FJ93ED)</td>
<td>CEFUROXIME</td>
<td>250 mg</td>
</tr>
</tbody>
</table>

**Inactive Ingredients**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)</td>
<td></td>
</tr>
<tr>
<td>CROSCARMELLOSE SODIUM (UNII: MDNQ5J9R9R)</td>
<td></td>
</tr>
<tr>
<td>HYPROMELLOSE 2910 (15 MPA.S) (UNII: 36SFW2JZ0W)</td>
<td></td>
</tr>
<tr>
<td>HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)</td>
<td></td>
</tr>
<tr>
<td>POLYETHYLENE GLYCOL 4000 (UNII: 4R4HFI6D95)</td>
<td></td>
</tr>
<tr>
<td>PROPYLENE GLYCOL (UNII: 6DC9Q167V3)</td>
<td></td>
</tr>
<tr>
<td>SODIUM LAURYL SULFATE (UNII: 368GB5141J)</td>
<td></td>
</tr>
<tr>
<td>TALC (UNII: 7SEV7J4R1U)</td>
<td></td>
</tr>
<tr>
<td>TITANIUM DIOXIDE (UNII: 15FIX9V2JP)</td>
<td></td>
</tr>
</tbody>
</table>

**Product Characteristics**

<table>
<thead>
<tr>
<th>Color</th>
<th>Shape</th>
<th>Size</th>
<th>Imprint Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHITE (white to off white)</td>
<td>OVAL (capsule shaped)</td>
<td>15mm</td>
<td>LUPIN; 302</td>
</tr>
</tbody>
</table>

**Marketing Information**

**Marketing Category**
- ANDA

**Application Number or Monograph Citation**
- ANDA065135

**Marketing Start Date**
- 07/25/2003

**Marketing End Date**
- 07/25/2003

Cefuroxime Axetil Tablets USP
500 mg – Bottle of 20s
NDC 68180-303-20 Bottles of 20
### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELLULOSE, MICROCRYSTALLINE</td>
<td>(UNII: OP1R32D61U)</td>
</tr>
<tr>
<td>CROSCARMELLOSE SODIUM</td>
<td>(UNII: 215851J809)</td>
</tr>
<tr>
<td>HYPROMELLOSE 1510 (15 MPA.S)</td>
<td>(UNII: 288500512096)</td>
</tr>
<tr>
<td>HYPROMELLOSE 2910 (15 MPA.S)</td>
<td>(UNII: 2857071F14)</td>
</tr>
<tr>
<td>POLYETHYLENE GLYCOL 4000</td>
<td>(UNII: 3861918115)</td>
</tr>
<tr>
<td>PROPYLENE GLYCOLO</td>
<td>(UNII: 6262862777)</td>
</tr>
<tr>
<td>SILICON DIOXIDE</td>
<td>(UNII: 17742186)</td>
</tr>
<tr>
<td>SODIUM LAURYL SULFATE</td>
<td>(UNII: 3604851861)</td>
</tr>
<tr>
<td>TALC</td>
<td>(UNII: 7165171461)</td>
</tr>
<tr>
<td>TITANIUM DIOXIDE</td>
<td>(UNII: 17742186)</td>
</tr>
</tbody>
</table>

### Product Characteristics

- **Color**: WHITE (white to off white)
- **Score**: no score
- **Shape**: OVAL (capsule shaped)
- **Size**: 19mm
- **Flavor**: Imprint Code: LUPIN;303

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:57297-303-60</td>
<td>60 in 1 BOTTLE, Type 0: Not a Combination Product</td>
<td>07/25/2003</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:57297-303-20</td>
<td>20 in 1 BOTTLE, Type 0: Not a Combination Product</td>
<td>07/25/2003</td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

- **Marketing Category**: ANDA
- **Application Number or Monograph Citation**: ANDA065135
- **Marketing Start Date**: 07/25/2003
- **Marketing End Date**: |

### Labeler

- **Name**: LUPIN LIMITED
- **NDC**: 57297-303-60

### Registrant

- **Name**: LUPIN LIMITED
- **NDC**: 57297-303-60

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUPIN LIMITED</td>
<td>72504448</td>
<td>manufacture(57357-343, 57357-303), pack(57357-303, 57357-303)</td>
</tr>
</tbody>
</table>

Revised: 5/2016